CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Analysis of MCL-1L, BCL-XL, PIM1, PIM2, PARP9, and PARP14 protein expression with western blot showed that 18 hours of IFNγ treatment both in the absence or presence of imatinib consistently upregulated MCL-1L, PARP9, and PARP14 protein expression in primary human CD34+ CML stem/progenitor cells obtained from three additional patients.